Role of FABP7 in tumor cell signaling

Kagawa, Yoshiteru; Umaru, Banlanjo Abdulaziz; Islam, Ariful; Shil, Subrata Kumar; Miyazaki, Hirofumi; Yamamoto, Yoshiyuki; Ogata, Masaki; Owada, Yuji

doi:10.1016/j.jbior.2018.09.006

Cited by 43 publications

(30 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, combined, these data suggest AGR2 may be a contributor to an aggressive meningioma phenotype and should be considered as a possible molecular marker or therapeutic target on the transcript or protein level. Similarly, the fatty acid-binding protein FABP7 was also among the top concordantly expressed genes with its overexpression previously reported to enhance the proliferation and migration of many tumour types [35]. Our validation studies showed FABP7 expression increased by WB but not by IHC in grade III meningioma compared to grade I.…”

Section: Discussionsupporting

confidence: 81%

Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma

Dunn

Lenis

Hilton

et al. 2020

Cancers

View full text Add to dashboard Cite

Meningioma are the most frequent primary intracranial tumour. Management of aggressive meningioma is complex, and development of effective biomarkers or pharmacological interventions is hampered by an incomplete knowledge of molecular landscape. Here, we present an integrated analysis of two complementary omics studies to investigate alterations in the “transcriptome–proteome” profile of high-grade (III) compared to low-grade (I) meningiomas. We identified 3598 common transcripts/proteins and revealed concordant up- and downregulation in grade III vs. grade I meningiomas. Concordantly upregulated genes included FABP7, a fatty acid binding protein and the monoamine oxidase MAOB, the latter of which we validated at the protein level and established an association with Food and Drug Administration (FDA)-approved drugs. Notably, we derived a plasma signature of 21 discordantly expressed genes showing positive changes in protein but negative in transcript levels of high-grade meningiomas, including the validated genes CST3, LAMP2, PACS1 and HTRA1, suggesting the acquisition of these proteins by tumour from plasma. Aggressive meningiomas were enriched in processes such as oxidative phosphorylation and RNA metabolism, whilst concordantly downregulated genes were related to reduced cellular adhesion. Overall, our study provides the first transcriptome–proteome characterisation of meningioma, identifying several novel and previously described transcripts/proteins with potential grade III biomarker and therapeutic significance.

show abstract

Section: Discussionsupporting

confidence: 81%

Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma

Dunn

Lenis

Hilton

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Most intriguingly, we identified that FABP7 might be a novel biomarker to predict the response to neoadjuvant chemotherapy. FABP7, a family member of fatty acid binding proteins (FABPs), is recognized to facilitate the transportation of fatty acids (FAs) across a variety of cell organelles, regulating their metabolism and other physiological activities [ 21 , 22 ]. Emerging studies have indicated that FABP7 was significantly involved in pathogenesis and progression of multiple cancer types and could be useful as a tumor marker [ 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer

et al. 2020

View full text Add to dashboard Cite

Background Early prediction of response to neoadjuvant chemotherapy (NAC) is critical in choosing appropriate chemotherapeutic regimen for patients with locally advanced breast cancer. Herein, we sought to identify potential biomarkers to predict the response to neoadjuvant chemotherapy for breast cancer patients. Methods Three genomic profiles acquired by microarray analysis from subjects with or without residual tumors after NAC downloaded from the GEO database were used to screen the differentially expressed genes (DEGs). An array of public databases, including ONCOMINE, cBioportal, Breast Cancer Gene Expression Miner v4.0, and the Kaplan Meir-plotter, etc., were used to evaluate the potential functions, related signaling pathway, as well as prognostic values of FABP7 in breast cancer. Anti-cancer drug sensitivity assay, real-time PCR, flow cytometry and western-blotting assays were used to investigate the function of FABP7 in breast cancer cells and examine the relevant mechanism. Results Two differentially expressed genes, including FABP7 and ESR1, were identified to be potential indicators of response to anthracycline and taxanes for breast cancer. FABP7 was associated with better chemotherapeutic response, while ESR1 was associated with poorer chemotherapeutic effectiveness. Generally, the expression of FABP7 was significantly lower in breast cancer than normal tissue samples. FABP7 mainly high expressed in ER-negative breast tumor and might regulate cell cycle to enhance chemosensitivity. Moreover, elevated FABP7 expression increased the percentage of cells at both S and G2/M phase in MDA-MB-231-ADR cells, and decreased the percentage of cells at G0/G1 phase, as compared to control group. Western-blotting results showed that elevated FABP7 expression could increase Skp2 expression, while decrease Cdh1 and p27kip1 expression in MDA-MB-231-ADR cells. In addition, FABP7 was correlated to longer recurrence-free survival (RFS) in BC patients with ER-negative subtype of BC treated with chemotherapy. Conclusion FABP7 is a potential favorable biomarker and predicts better response to NAC in breast cancer patients. Future study on the predictive value and detail molecular mechanisms of FABP7 in contribution to chemosensitivity in breast cancer is warranted.

show abstract

“…Most intriguingly, we identi ed that FABP7 might be a novel biomarker to predict the response to neoadjuvant chemotherapy. FABP7, a family member of fatty acid binding proteins (FABPs), is recognized to facilitate the transportation of fatty acids (FAs) across a variety of cell organelles, regulating their metabolism and other physiological activities [21,22]. Emerging studies have indicated that FABP7 was signi cantly involved in pathogenesis and progression of multiple cancer types and could be useful as a tumor marker [22,23].…”

Section: Discussionmentioning

confidence: 99%

FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer 

Xie

Xiao

Jia

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Early prediction of response to neoadjuvant chemotherapy (NAC) is critical in choosing appropriate chemotherapeutic regimen for patients with locally advanced breast cancer. Herein, we sought to identify potential biomarkers to predict the response to neoadjuvant chemotherapy for breast cancer patients.Methods: Three genomic profiles acquired by microarray analysis from subjects with or without residual tumors after NAC downloaded from the GEO database were used to screen the differentially expressed genes (DEGs). An array of public databases, including ONCOMINE, cBioportal, Breast Cancer Gene Expression Miner v4.0, and the Kaplan Meir-plotter, etc., were used to evaluate the potential functions, related signaling pathway, as well as prognostic values of FABP7 in breast cancer. Anti-cancer drug sensitivity assay, real-time PCR, ﬂow cytometry and western-blotting assays were used to investigate the function of FABP7 in breast cancer cells and examine the relevant mechanism.Results: Two differentially expressed genes, including FABP7 and ESR1, were identified to be potential indicators of response to anthracycline and taxanes for breast cancer. FABP7 was associated with better chemotherapeutic response, while ESR1 was associated with poorer chemotherapeutic effectiveness. Generally, the expression of FABP7 was significantly lower in breast cancer than normal tissue samples. FABP7 mainly high expressed in ER-negative breast tumor and might regulate cell cycle to enhance chemosensitivity. Moreover, elevated FABP7 expression increased the percentage of cells at both S and G2/M phase in MDA-MB-231-ADR cells, and decreased the percentage of cells at G0/G1 phase, as compared to control group. Western-blotting results showed that elevated FABP7 expression could increase Skp2 expression, while decrease CDH1 and p27kip1 expression in MDA-MB-231-ADR cells. In addition, FABP7 was correlated to longer recurrence-free survival (RFS) in BC patients with ER-negative subtype of BC treated with chemotherapy. Conclusion: FABP7 is a potential favorable biomarker and predicts better response to NAC in breast cancer patients. Future study on the predictive value and detail molecular mechanisms of FABP7 in contribution to chemosensitivity in breast cancer is warranted.

show abstract

Role of FABP7 in tumor cell signaling

Cited by 43 publications

References 124 publications

Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma

Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma

FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer

FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer

Contact Info

Product

Resources

About

Role of FABP7 in tumor cell signaling

Cited by 43 publications

References 124 publications

Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma

Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma

FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer

FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer&nbsp;

Contact Info

Product

Resources

About

FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer